Shots:
- The two companies collaborated to facilitate the development of digital health tools for the earlier screening of cardiovascular diseases, including HF
- AstraZeneca and Eko will accelerate the development of Eko algorithms, enhancing clinical trials with Eko technology, and potentially building new HF detection solutions. The agreement allows the companies to harness the potential to improve access to individualized care and generate better patient outcomes
- In Dec’2019, Eko has received the US FDA’s BT designation for a novel ECG-based algorithm that can identify reduced LVEF. If approved, the algorithm will be compatible with the DUO, Eko’s handheld stethoscope, and ECG device
Click here to read full press release/ article | Ref: PRNewswire | Image: Physician Practice
